Multiple System Atrophy is an uncommon degenerative neurological condition that affects involuntary (hot) body systems such as blood pressure, respiration, bladder function, and movement control.

Olivopontocerebellar atrophy, also known as Shai-Drager syndrome, or striatonigral degeneration (MSA), shares many of the same symptoms as Parkinson's disease, such as slow performance, tight muscles, and poor balance.

Multiple System Atrophy Causes

There are currently no known causes of systemic atrophy. Some of the researchers study the heritable component, or the involvement of the opinion, in the course of the disease, but there is no evidence to support these theories.

Multiple System Atrophy Treatment

There is no treatment available to slow or stop the progression of Multiple system atrophy. At the moment, the existing  Multiple system atrophy treatment is symptomatic and includes the medications used to treat the symptoms of Parkinson's disease, orthostatic hypotension, signs and symptoms, urination, and sexual dysfunction. Patients are usually short and small operations with a limited drug arsenal. A general treatment goal is to control the signs and symptoms, taking antiparkinsonian drugs, such as L-dopa, carbidopa, and treating orthostatic hypotension, which is associated with an increase in the quantities of salt to the liquid.

Multiple System Atrophy Market

Medications to increase blood pressure, which is salt-retaining steroids, are often necessary; however, their side effects might be triggered and need to be closely monitored by a healthcare professional. Dihydroxyphenylserine will help to replace the chemical signals, called neurotransmitters, to reduce the autonomic nervous system in amyotrophic lateral sclerosis.

The drug increases levels of the neurotransmitter gamma-aminobutyric acid (GABA) and can reduce cerebellar ataxia in some patients. For this purpose, medicinal drugs, antidepressants, the pituitary gland, skin, hormones, and others, improve the patient's ability to walk.

The subsequent advances in the field of research and development are the most likely cause that the actual treatment of Multiple system atrophy patients is to be improved, it is likely that the increase in the revenue growth of the Multiple system atrophy therapy market during the forecast period (2017-2028).

Multiple System Atrophy (MSA) Therapies along with Key Pharma Players:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.